Epstein Secrets

s set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. Amanda Ens EFTA00820342 Director B

den of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/Amneal/Synthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given

s set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. EFTA00820351 Amanda Ens Director B

rden of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/AmneaUSynthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given

s set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. Amanda Ens Director Bank of America

den of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/Amneal/Synthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given